Life Sciences Insight

4D Lifetec Raises $1.9M in Series B Financing to Support Lung Cancer Detection Test Launch

NEW YORK – Swiss diagnostics firm 4D Lifetec said Friday that it has raised CHF 1.9 million ($1.9 million) in a first closing of its Series B round, supported by both existing and new investors as well as strategic partners.

The company said it anticipates completing the Series B round by the end of 2022.

The company has developed a lung cancer early cancer detection assay that employs ex vivo UV-B radiation of peripheral blood mononuclear blood cells, combined with high performing single-cell gel electrophoresis.

4D said it will use the investment to support the launch of the test in Europe this year and in the US in 2023. In parallel, the firm said it is working with strategic partners to automate its assay workflow in anticipation of future customer needs for higher throughput capabilities.

4D Lifetec CEO Arne Faisst said in a statement that the financing will allow the company to maintain activities supporting its ongoing European launch, as well as begin establishing a lab in the US. “We are sincerely gratified by the long-term commitment of our existing investors and welcome our new private and strategic investors helping us to prepare the company for its next growth phase,” Faisst said.

SHARE
Facebook
Twitter
LinkedIn